Cargando…

The Prognostic Value of BRCA1 mRNA Expression Levels Following Neoadjuvant Chemotherapy in Breast Cancer

BACKGROUND: A fraction of sporadic breast cancers has low BRCA1 expression. BRCA1 mutation carriers are more likely to achieve a pathological complete response with DNA-damage-based chemotherapy compared to non-mutation carriers. Furthermore, sporadic ovarian cancer patients with low levels of BRCA1...

Descripción completa

Detalles Bibliográficos
Autores principales:	Margeli, Mireia, Cirauqui, Beatriz, Castella, Eva, Tapia, Gustavo, Costa, Carlota, Gimenez-Capitan, Ana, Barnadas, Agusti, Ronco, Maria Sanchez, Benlloch, Susana, Taron, Miquel, Rosell, Rafael
Formato:	Texto
Lenguaje:	English
Publicado:	Public Library of Science 2010
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2831058/ https://www.ncbi.nlm.nih.gov/pubmed/20209131 http://dx.doi.org/10.1371/journal.pone.0009499

Ejemplares similares

mRNA expression levels and genetic status of genes involved in the EGFR and NF-κB pathways in metastatic non-small-cell lung cancer patients
por: Santarpia, Mariacarmela, et al.
Publicado: (2011)

The predictive value of 53BP1 and BRCA1 mRNA expression in advanced non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy
por: Bonanno, Laura, et al.
Publicado: (2013)

Prognostic value of hematogenous dissemination and biological profile of the tumor in early breast cancer patients: A prospective observational study
por: Solá, Montserrat, et al.
Publicado: (2011)

Combinatory effect of BRCA1 and HERC2 expression on outcome in advanced non-small-cell lung cancer
por: Bonanno, Laura, et al.
Publicado: (2016)

High Proliferation Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Early Breast Cancer
por: Alba, Emilio, et al.
Publicado: (2016)

Tumor BRCA1, RRM1 and RRM2 mRNA Expression Levels and Clinical Response to First-Line Gemcitabine plus Docetaxel in Non-Small-Cell Lung Cancer Patients
por: Boukovinas, Ioannis, et al.
Publicado: (2008)

Pre- and Post-Neoadjuvant Clinicopathological Parameters Can Help in the Prognosis and the Prediction of Response in HER2+ and Triple Negative Breast Cancer
por: Pons, Laura, et al.
Publicado: (2023)

Predictive value of BRCA1/2 mRNA expression for response to neoadjuvant chemotherapy in BRCA‐negative breast cancers
por: Xu, Ye, et al.
Publicado: (2017)

Conventional and digital Ki67 evaluation and their correlation with molecular prognosis and morphological parameters in luminal breast cancer
por: Pons, Laura, et al.
Publicado: (2022)

Plasma mRNA expression levels of BRCA1 and TS as potential predictive biomarkers for chemotherapy in gastric cancer
por: Shen, Jie, et al.
Publicado: (2014)

Effector Mechanisms of CD8+ HLA-DR+ T Cells in Breast Cancer Patients Who Respond to Neoadjuvant Chemotherapy
por: Osuna-Gómez, Rubén, et al.
Publicado: (2021)

Nanoparticle albumin-bound paclitaxel in a patient with locally advanced breast cancer and taxane-induced skin toxicity: a case report
por: Cirauqui, Beatriz Cirauqui, et al.
Publicado: (2014)

Customized Treatment in Non-Small-Cell Lung Cancer Based on EGFR Mutations and BRCA1 mRNA Expression
por: Rosell, Rafael, et al.
Publicado: (2009)

Chromosome 17 Centromere Duplication and Responsiveness to Anthracycline-Based Neoadjuvant Chemotherapy in Breast Cancer()()
por: Tibau, Ariadna, et al.
Publicado: (2014)

Endobronchial ultrasound-guided transbronchial needle aspiration in the diagnosis of intrathoracic lymph node metastases from extrathoracic malignancies
por: Sanz-Santos, Jose, et al.
Publicado: (2012)

BRCA1 Expression and Outcome in Patients With EGFR-Mutant NSCLC Treated With Gefitinib Alone or in Combination With Olaparib
por: Karachaliou, Niki, et al.
Publicado: (2020)

BRCA1: A Novel Prognostic Factor in Resected Non-Small-Cell Lung Cancer
por: Rosell, Rafael, et al.
Publicado: (2007)

Neoadjuvant chemotherapy with Cisplatin in BRCA1 mutation carriers – results of treatment
por: Byrski, T, et al.
Publicado: (2012)

Germline BRCA, chemotherapy response scores, and survival in the neoadjuvant treatment of ovarian cancer
por: Lee, Yong Jae, et al.
Publicado: (2020)

Analysis of extracellular vesicle mRNA derived from plasma using the nCounter platform
por: Bracht, Jillian W. P., et al.
Publicado: (2021)

Platinum-Based Neoadjuvant Chemotherapy for Breast Cancer With BRCA Mutations: A Meta-Analysis
por: Wang, Chang-Jun, et al.
Publicado: (2020)

Mutations of BRCA1, BRCA2, and PALB2 Genes in Breast Tumor Tissue: Relationship with the Effectiveness of Neoadjuvant Chemotherapy and Disease Prognosis
por: Tsyganov, Matvey M., et al.
Publicado: (2023)

Clinical Validation of a PCR Assay for the Detection of EGFR Mutations in Non–Small-Cell Lung Cancer: Retrospective Testing of Specimens from the EURTAC Trial
por: Benlloch, Susana, et al.
Publicado: (2014)

Molecular Detection of Peripheral Blood Breast Cancer mRNA Transcripts as a Surrogate Biomarker for Circulating Tumor Cells
por: Lasa, Adriana, et al.
Publicado: (2013)

Differential effect of MMSET mRNA levels on survival to first-line FOLFOX and second-line docetaxel in gastric cancer
por: Wei, J, et al.
Publicado: (2014)

Real-world data on T-DM1 efficacy – results of a single-center retrospective study of HER2-positive breast cancer patients
por: Hardy-Werbin, Max, et al.
Publicado: (2019)

Neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients
por: Byrski, T, et al.
Publicado: (2011)

BRCA1 and BRCA2 mRNA-expression prove to be of clinical impact in ovarian cancer
por: Tsibulak, Irina, et al.
Publicado: (2018)

Quantifying BRCA1 and BRCA2 mRNA Isoform Expression Levels in Single Cells
por: Lattimore, Vanessa L., et al.
Publicado: (2019)

Impact of BRCA Mutation Status on Tumor Infiltrating Lymphocytes (TILs), Response to Treatment, and Prognosis in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
por: Grandal, Beatriz, et al.
Publicado: (2020)

c-Met Mutational Analysis in the Sema and Juxtamembrane Domains in Small-Cell-Lung-Cancer
por: de Aguirre, Itziar, et al.
Publicado: (2006)

Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Cancer. Final Results of the Multicentre Phase II CAPRICE Study
por: Gil-Gil, Miguel J., et al.
Publicado: (2021)

Resveratrol increases BRCA1 and BRCA2 mRNA expression in breast tumour cell lines
por: Fustier, P, et al.
Publicado: (2003)

Platinum-based neoadjuvant chemotherapy in BRCA1-positive breast cancer: a retrospective cohort analysis and literature review
por: Sæther, Nikolai Havn, et al.
Publicado: (2018)

The effect of neoadjuvant platinum-based chemotherapy in BRCA mutated triple negative breast cancers -systematic review and meta-analysis
por: Caramelo, Olga, et al.
Publicado: (2019)

Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine
por: Souglakos, J, et al.
Publicado: (2008)

Clinical significance of BRCA1 and BRCA2 mRNA and protein expression in patients with sporadic gastric cancer
por: Kim, Hee Sung, et al.
Publicado: (2019)

Combinatorial Blood Platelets-Derived circRNA and mRNA Signature for Early-Stage Lung Cancer Detection
por: D’Ambrosi, Silvia, et al.
Publicado: (2023)

Pathological complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients
por: Byrski, Tomasz, et al.
Publicado: (2015)

Exemestane as primary treatment of oestrogen receptor-positive breast cancer in postmenopausal women: a phase II trial
por: Barnadas, A, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_6d64sas3qdnm1gtsq4nb60i24m